WUHN — Wuhan General (China) Share Price
Last trade - 00:00- $0.00m
- $100.01m
- $80.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | 263.24 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.07% | ||
| Return on Equity | -9.43% | ||
| Operating Margin | -2.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 118.63 | 92.34 | 110.31 | 127.5 | 80.38 | n/a | n/a | -0.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +157.35 | -6.42 | -55.36 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Wuhan General Group (China) Inc is a South Africa-based bioceutical company. The Company is focused on alternative plant-based cannabinoids and mental health therapeutic research. Through its subsidiary, Neur.ai, the Company is engaged in developing a portfolio of receptor agonists based on neurotransformational medicine for the treatment of mental illness. The Company develops and commercializes a range of cannabidiol (CBD) and mushrooms-based products under the Dr. AnnaRx, Medspresso, and Liviana brands. The brands span across a range of premium CBD- and mushroom-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. In addition, the Company's research and clinical trials with psilocybin are aimed at new therapies that seek to help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Its Liviana brand offers CBD-infused raw honey and CBD-infused extra virgin olive oils.
Directors
- Jeffrey Robinson CEO
- Luka Marjanovic DHR
- Selah Abrams OTH
- Rameez Adair OTH
- Riyad Domingo OTH
- Willem Jonker OTH
- Ramy Kamaneh OTH (36)
- Johann McLoughlin OTH
- Robert Simbowe OTH
- Anna Morera SEC
- Last Annual
- December 31st, 2012
- Last Interim
- December 31st, 2012
- Incorporated
- September 12th, 2006
- Public Since
- April 1st, 1998
- No. of Shareholders
- 141
- No. of Employees
- 700
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 55,149,662
- Address
- Unit 1, CAPE TOWN, 7925
- Web
- https://m2bio.co/
- Phone
- +1 5149287368
- Auditors
- Samuel H. Wong & Co.
Similar to WUHN
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:24 UTC, shares in Wuhan General (China) are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Wuhan General (China) last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Wuhan General (China) share price has underperformed the S&P500 Index by -100% over the past year.
There is no consensus recommendation for this security.
Wuhan General (China) does not currently pay a dividend.
Wuhan General (China) does not currently pay a dividend.
Wuhan General (China) does not currently pay a dividend.
To buy shares in Wuhan General (China) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Wuhan General (China) had a market capitalisation of $0.00m.
Here are the trading details for Wuhan General (China):
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: WUHN
Based on an overall assessment of its quality, value and momentum Wuhan General (China) is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wuhan General (China). Over the past six months, its share price has underperformed the S&P500 Index by -99.78%.
As of the last closing price of $0.00, shares in Wuhan General (China) were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Wuhan General (China) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Wuhan General (China)'s management team is headed by:
- Jeffrey Robinson - CEO
- Luka Marjanovic - DHR
- Selah Abrams - OTH
- Rameez Adair - OTH
- Riyad Domingo - OTH
- Willem Jonker - OTH
- Ramy Kamaneh - OTH
- Johann McLoughlin - OTH
- Robert Simbowe - OTH
- Anna Morera - SEC